Hostname: page-component-76d6cb85b7-8p85h Total loading time: 0 Render date: 2026-07-21T06:54:28.135Z Has data issue: false hasContentIssue false
  • English
  • Français

Reviewer Comment on Momen et al. “Demographic and Clinical Characteristics of Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder in Canadian Adults”

Published online by Cambridge University Press:  10 April 2026

Ann Subota Open the ORCID record for Ann Subota [Opens in a new window]
Ann Subota*
Affiliation:
Department of Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Canada
*
Corresponding author: Ann Subota; Email: ann.subota@ucalgary.ca
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Reviewer Comment
Information
Canadian Journal of Neurological Sciences , First View , pp. 1
Copyright
© The Author(s), 2026. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Momen, AI, Freedman, MS, Fadda, G, et al. Demographic and clinical characteristics of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder in Canadian adults. Can J Neurol Sci. 2026.Google Scholar
Leitner, U, Chew, SH, Blanch, J, et al. Characteristics of MRI lesions in AQP4 antibody-positive NMOSD, MOGAD, and multiple sclerosis: A systematic review and meta-analysis. J Neurol. 2025;272(9):560. doi: 10.1007/s00415-025-13303-w.CrossRefGoogle ScholarPubMed
Cobo-Calvo, Á., Gómez-Ballesteros, R, Orviz, A, et al. Therapeutic inertia in the management of neuromyelitis optica spectrum disorder. Front Neurol. 2024;15:1341473. doi: 10.3389/fneur.2024.1341473.CrossRefGoogle ScholarPubMed
Paul, F, Marignier, R, Palace, J, et al. International Delphi consensus on the management of AQP4-IgG+ NMOSD: Recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflammation. 2023;10(4):e200124. doi: 10.1212/NXI.0000000000200124.CrossRefGoogle ScholarPubMed
Prain, K, Woodhall, M, Vincent, A, et al. AQP4 antibody assay sensitivity comparison in the era of the 2015 diagnostic criteria for NMOSD. Front Neurol. 2019;10:1028. doi: 10.3389/fneur.2019.01028.CrossRefGoogle ScholarPubMed